Duchenne Muscular Dystrophy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
170 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5934390

Duchenne Muscular Dystrophy (DMD), a genetic disorder that leads to muscle degeneration, continues to affect individuals worldwide. While the condition is primarily X-linked recessive, it can also be inherited from parents or caused by new mutations. Despite numerous therapies and drugs to manage DMD, there is currently no cure for this debilitating disease.

Factors Driving the Global Duchenne Muscular Dystrophy Market

Several factors are propelling the global Duchenne Muscular Dystrophy market forward. These include:

Introduction of Novel Drugs and Therapies: The market is witnessing the introduction of innovative drugs and therapies aimed at managing DMD more effectively.
Disease-Modifying Therapies: The development of disease-modifying therapies is offering hope for improved quality of life for DMD patients.
Support from Companies: Strong support from pharmaceutical and biotech companies in the research and development of DMD treatments is making a significant impact.
Advocacy Groups: Patient advocacy groups are actively involved in the regulatory approval process, advocating for faster access to promising treatments.
Mutation-Specific Therapies: Mutation-specific therapies are emerging as a potential breakthrough in DMD treatment.

Focus on Early Intervention and Last-Stage Patients

Drug developers are increasingly concentrating on developing therapies targeting newborns, young infants, and even patients in the last stages of DMD. Over the past few years, there has been rapid development in DMD therapeutics. However, a significant portion of patients still cannot benefit from available treatments due to their high cost and lack of awareness.

Corticosteroids Leading the Way

Among the various products available for DMD treatment, corticosteroids are expected to lead the market. By the end of 2026, corticosteroids are projected to surpass US$9,000 million in revenue. Scientific research indicates that corticosteroids can improve muscle strength for up to two to five years, although the long-term benefits remain uncertain.

Hospital Pharmacies as Key Distribution Channels

Hospital pharmacies are poised to be the largest distribution channel for DMD treatments between 2024 and 2031. The increasing hospitalization of DMD patients and government investments in healthcare infrastructure are contributing to the growth of hospital pharmacies.

Mutation Suppression Therapy Gaining Favor

Mutation suppression therapy is becoming a highly preferred treatment option for DMD. By 2026, it is projected to generate over US$6,000 million in revenue. This therapy targets specific mutations responsible for DMD, offering potential benefits to patients. Several mutation suppression therapies are undergoing clinical trials, with some on the verge of FDA approval.

Regional Trends

Europe is anticipated to emerge as a leading region in the global DMD market by 2026. North America and the Asia Pacific Excluding Japan (APEJ) are also expected to experience robust growth between 2024 and 2031.

Key Players in the Global DMD Market

Prominent companies in the global Duchenne Muscular Dystrophy market include ITALFARMACO S.p.A., FibroGen, Inc., Summit Therapeutics plc, PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.

Market Segmentation

Product Type

NSAIDs
Corticosteroids
Other Products

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Therapy

Mutation Suppression
Exon Skipping Approach
Others Therapies

Region

North America
Latin America
Europe
Asia-Pacific
Middle East and Africa

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Duchenne Muscular Dystrophy Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

3.1. Global Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. NSAIDs
3.1.1.2. Corticosteroids
3.1.1.3. Other Products
3.2. Global Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Hospital Pharmacies
3.2.1.2. Retail Pharmacies
3.2.1.3. Online Pharmacies
3.3. Global Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Mutation Suppression
3.3.1.2. Exon Skipping Approach
3.3.1.3. Others Therapies
3.4. Global Duchenne Muscular Dystrophy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

4.1. North America Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. NSAIDs
4.1.1.2. Corticosteroids
4.1.1.3. Other Products
4.2. North America Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospital Pharmacies
4.2.1.2. Retail Pharmacies
4.2.1.3. Online Pharmacies
4.3. North America Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Mutation Suppression
4.3.1.2. Exon Skipping Approach
4.3.1.3. Others Therapies
4.4. North America Duchenne Muscular Dystrophy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

5.1. Europe Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. NSAIDs
5.1.1.2. Corticosteroids
5.1.1.3. Other Products
5.2. Europe Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospital Pharmacies
5.2.1.2. Retail Pharmacies
5.2.1.3. Online Pharmacies
5.3. Europe Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Mutation Suppression
5.3.1.2. Exon Skipping Approach
5.3.1.3. Others Therapies
5.4. Europe Duchenne Muscular Dystrophy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. NSAIDs
6.1.1.2. Corticosteroids
6.1.1.3. Other Products
6.2. Asia Pacific Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospital Pharmacies
6.2.1.2. Retail Pharmacies
6.2.1.3. Online Pharmacies
6.3. Asia Pacific Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Mutation Suppression
6.3.1.2. Exon Skipping Approach
6.3.1.3. Others Therapies
6.4. Asia Pacific Duchenne Muscular Dystrophy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

7.1. Latin America Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. NSAIDs
7.1.1.2. Corticosteroids
7.1.1.3. Other Products
7.2. Latin America Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Hospital Pharmacies
7.2.1.2. Retail Pharmacies
7.2.1.3. Online Pharmacies
7.3. Latin America Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Mutation Suppression
7.3.1.2. Exon Skipping Approach
7.3.1.3. Others Therapies
7.4. Latin America Duchenne Muscular Dystrophy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. NSAIDs
8.1.1.2. Corticosteroids
8.1.1.3. Other Products
8.2. Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospital Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Online Pharmacies
8.3. Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Mutation Suppression
8.3.1.2. Exon Skipping Approach
8.3.1.3. Others Therapies
8.4. Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Duchenne Muscular Dystrophy Treatment Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Duchenne Muscular Dystrophy Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Duchenne Muscular Dystrophy Treatment Market Therapy, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product Type vs Therapy Heatmap
9.2. Manufacturer vs Therapy Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Sarepta Therapeutics, Inc
9.5.1.1. Company Overview
9.5.1.2. Product Type Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Santhera Pharmaceuticals
9.5.2.1. Company Overview
9.5.2.2. Product Type Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. PTC Therapeutics
9.5.3.1. Company Overview
9.5.3.2. Product Type Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Summit Therapeutics plc
9.5.4.1. Company Overview
9.5.4.2. Product Type Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. FibroGen, Inc
9.5.5.1. Company Overview
9.5.5.2. Product Type Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. ITALFARMACO S.p.A.
9.5.6.1. Company Overview
9.5.6.2. Product Type Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Sarepta Therapeutics, Inc
Santhera Pharmaceuticals
PTC Therapeutics
Summit Therapeutics plc
FibroGen, Inc
ITALFARMACO S.p.A.

Methodology

LOADING...

Factors Driving the Global Duchenne Muscular Dystrophy Market

Focus on Early Intervention and Last-Stage Patients

Corticosteroids Leading the Way

Hospital Pharmacies as Key Distribution Channels

Mutation Suppression Therapy Gaining Favor

Regional Trends

Europe is anticipated to emerge as a leading region in the global DMD market by 2026. North America and the Asia Pacific Excluding Japan (APEJ) are also expected to experience robust growth between 2024 and 2031.

Key Players in the Global DMD Market

Market Segmentation

Product Type

Distribution Channel

Therapy

Region

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Duchenne Muscular Dystrophy Treatment Market

Duchenne Muscular Dystrophy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

Duchenne Muscular Dystrophy Drugs Market by Drug Type, by Distribution Channel, and By Region

Duchenne Muscular Dystrophy Global Market Report 2024

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report